Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX2 | P34913 | 5/20 | 0.42 |
| ▸ | CYP3A4 | P08684 | 12/20 | 0.40 |
| ▸ | MC4R | P32245 | 12/20 | 0.40 |
| ▸ | FPR3 | P25089 | 1/20 | 0.38 |
| ▸ | FPR2 | P25090 | 1/20 | 0.38 |
| ▸ | CNR1 | P21554 | 1/20 | 0.38 |
| ▸ | CNR2 | P34972 | 1/20 | 0.38 |
| ▸ | DRD2 | P14416 | 1/20 | 0.37 |
| ▸ | HTR2A | P28223 | 1/20 | 0.37 |
| ▸ | HTR2C | P28335 | 1/20 | 0.37 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12713130 | 0.85 | MC4R (0.47) | EPHX2CYP3A4MC4R | |
| SCHEMBL13948680 | 0.84 | MEN1 (0.38) | EPHX2CYP3A4MC4R | |
| SCHEMBL13940674 | 0.82 | MEN1 (0.45) | EPHX2 | |
| SCHEMBL13940673 | 0.80 | EPHX2 (0.41) | EPHX2 | |
| SCHEMBL14435563 | 0.77 | HDAC8 (0.48) | EPHX2MC4RFPR3FPR2 | |
| SCHEMBL13948344 | 0.73 | ADAM17 (0.44) | CYP3A4MC4R | |
| SCHEMBL12713282 | 0.73 | MC4R (0.42) | EPHX2CYP3A4MC4RFPR3FPR2 | |
| SCHEMBL12713117 | 0.72 | MC4R (0.51) | EPHX2CYP3A4MC4R | |
| SCHEMBL14431088 | 0.72 | HDAC8 (0.52) | EPHX2MC4RFPR3FPR2 | |
| SCHEMBL14435216 | 0.72 | HDAC8 (0.54) | EPHX2MC4RFPR3FPR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2020405-A1 | Substituted aryl or heteroarylpiperidine derivatives as melanocortin-4 receptor modulators | Santhera Pharmaceuticals (Schweiz) AG (CH) | 2009-02-04 | — | — | EP | disclosed |